Delving into the Latest Updates on The United Bio-Technology(Hengqin) Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Urogenital Diseases

Synthetic peptide

Recombinant polypeptide

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	7

Top 5 Drug Type	Count

Biosimilar	4
Synthetic peptide	2
Recombinant polypeptide	2
Hormone	2
Small molecule drug	1

Top 5 Target	Count

GLP-1R(Glucagon-like peptide 1 receptor)	2
INSR(Insulin receptor)	1
NPY2R(Neuropeptide Y receptor type 2)	1
SOST(Sclerostin)	1
GLP-1R x INSR	1

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose，6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.

Start Date22 Aug 2025

Sponsor / Collaborator

The United Bio-Technology(Hengqin) Co., Ltd.

NCT07134335

/ Active, not recruitingPhase 2

A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population

This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population

Start Date11 Jul 2025

Sponsor / Collaborator

The United Bio-Technology(Hengqin) Co., Ltd.

CTR20250029

/ Active, not recruitingPhase 2

评估UBT251注射液在2型糖尿病患者中有效性和安全性的随机、双盲、安慰剂及阳性药平行对照Ⅱ期研究

[Translation] A randomized, double-blind, placebo- and active drug-controlled phase II study to evaluate the efficacy and safety of UBT251 injection in patients with type 2 diabetes

主要目的：在2型糖尿病患者中评价UBT251注射液连续给药24周后的有效性，为Ⅲ期临床试验推荐给药剂量。次要目的：1）评价UBT251注射液连续给药24周在2型糖尿病患者中的安全性；2）评价UBT251注射液在2型糖尿病患者中的药代/药效动力学特征；3）评价UBT251注射液在2型糖尿病患者中的免疫原性特征；4）评价UBT251注射液对2型糖尿病患者胰岛功能的影响。

[Translation]

Primary objective: To evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes and to recommend the dosage for Phase III clinical trials. Secondary objectives: 1) To evaluate the safety of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes; 2) To evaluate the pharmacokinetic/pharmacodynamic characteristics of UBT251 injection in patients with type 2 diabetes; 3) To evaluate the immunogenicity characteristics of UBT251 injection in patients with type 2 diabetes; 4) To evaluate the effect of UBT251 injection on pancreatic islet function in patients with type 2 diabetes.

Start Date15 Mar 2025

Sponsor / Collaborator

The United Bio-Technology(Hengqin) Co., Ltd.

100 Clinical Results associated with The United Bio-Technology(Hengqin) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with The United Bio-Technology(Hengqin) Co., Ltd.

Login to view more data

100 Deals associated with The United Bio-Technology(Hengqin) Co., Ltd.

Login to view more data

100 Translational Medicine associated with The United Bio-Technology(Hengqin) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

IND Application

IND Approval

1

Phase 1

Phase 2

1

Phase 3

NDA/BLA

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Liraglutide biosimilar(Zhuhai United Laboratories) ( GLP-1R )	Diabetes Mellitus, Type 2 More	Approved
Semaglutide biosimilar (Zhuhai United Laboratories) ( GLP-1R )	Obesity More	NDA/BLA
Insulin degludec/liraglutide biosimilar (Federal Biotechnology (Zhuhai Hengqin)) ( GLP-1R x INSR )	Diabetes Mellitus, Type 2 More	Phase 3
UBT-251 ( GCGR x GIPR x GLP-1R )	Obesity More	Phase 2
Insulin degludec/Insulin aspart(Federal Biotechnology (Zhuhai Hengqin)) ( INSR )	Diabetes Mellitus, Type 2 More	Phase 1